Compare Virgin Galactic Holdings, Inc. (SPCE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs TransMedics Group Inc — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.87 (market cap $445.69M), while TransMedics Group Inc trades at $77.52 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 6.1× Virgin Galactic Holdings, Inc.'s market cap, and TransMedics Group Inc is more actively traded (949,331 versus 5,128,850). Which is the better fit depends on your goals — on Pluang, investors hold Virgin Galactic Holdings, Inc. for 69 Days and TransMedics Group Inc for 24 Days on average.
| SPCE | TMDX | |
|---|---|---|
Market Cap | $445.69M | $2.74B |
Volume | 5,128,850 | 949,331 |
Sector | Industrials | Health |
52-Week High | $7.52 | $150.42 |
52-Week Low | $2.17 | $61.99 |
Typical Hold Time | 69 Days | 24 Days |
Enterprise Value | $409.68M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCE trades at $2.875, down 4.49% on the day, reflecting ongoing volatility amid negative profitability and cash burn. The company continues to post significant losses, with a net income margin of -23,867.44% in 2025, though recent quarters have shown smaller-than-expected EPS losses. Technical indicators are bearish, with moving averages signaling selling pressure, while RSI levels suggest potential oversold conditions. Recent news highlights a delay in commercial Delta flights to 2027 but strong ticket demand and a legal settlement resolution.
The outlook remains high-risk due to persistent cash outflows and delayed revenue growth, yet long-term potential in space tourism offers speculative upside. Investment hinges on successful execution of the 2027 cash flow target and commercial flight timeline, but shareholder dilution and high short interest pose substantial risks. Analyst consensus is mixed, with 29% buy ratings reflecting cautious optimism amid fundamental challenges.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
